GCM
MLTX icon

Graham Capital Management’s MoonLake Immunotherapeutics MLTX Stock Holding History

Graham Capital Management’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$393K Sell
21,089
-3,203
-13% -$53.1K 0.01% 709
2025
Q4 		$320K Buy
+24,292
New +$287K 0.01% 830
2023
Q4 		– Sell
-4,352
Closed -$248K – 1198
2023
Q3 		$248K Buy
+4,352
New +$240K 0.01% 787

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Graham Capital Management's MLTX Position: Q1 2026 in Review

Graham Capital Management reduced its MoonLake Immunotherapeutics (MLTX) stake by 13% in Q1 2026, selling an estimated $53.1K and leaving 21,089 shares worth $393K. The position accounts for 0.01% of the portfolio, ranked #709.

Graham Capital Management first reported a position in MLTX in Q3 2023 and has held it in 3 quarters since. 147 funds tracked by Wall St. Rank hold MLTX as of Q1 2026.

  • Graham Capital Management held 21,089 shares of MoonLake Immunotherapeutics worth $393K as of Q1 2026.
  • Graham Capital Management sold 3,203 MoonLake Immunotherapeutics shares in Q1 2026, an estimated $53.1K.
  • MoonLake Immunotherapeutics made up 0.01% of Graham Capital Management's portfolio in Q1 2026, its #709 holding.
  • Graham Capital Management first reported a position in MoonLake Immunotherapeutics in Q3 2023 and has held it in 3 quarters since.
  • 147 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q1 2026.

Based on Graham Capital Management's 13F filing for Q1 2026, filed 15 May 2026.